- Home
- RGTI vs ELVN Comparison
RGTI vs ELVN Comparison
Compare RGTI & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RGTI | ELVN |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.2B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RGTI | ELVN |
|---|---|---|
| Price | $12.11 | $51.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 14 |
| Target Price | $27.69 | ★ $74.33 |
| AVG Volume (30 Days) | ★ 11.8M | 1.5M |
| Earning Date | 11-10-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.78 | 3.17 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $13,102,000.00 | N/A |
| Revenue This Year | $228.15 | N/A |
| Revenue Next Year | $88.82 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 59.86 | N/A |
| 52 Week Low | $9.19 | $14.79 |
| 52 Week High | $31.65 | $62.32 |
Technical Indicators
Market Signals| Indicator | RGTI | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 48.25 | 66.30 |
| Support Level | $11.11 | $37.77 |
| Resistance Level | $12.59 | $52.39 |
| Average True Range (ATR) | 0.89 | 2.18 |
| MACD | 0.23 | 1.29 |
| Stochastic Oscillator | 73.48 | 93.57 |
Price Performance
Historical ComparisonAbout RGTI Rigetti Computing Inc.
Rigetti Computing Inc builds quantum computers and the superconducting quantum processors that power them. The Company sells 9-qubit to 108-qubit quantum computing systems under the Novera and Cepheus trade names. Through the Rigetti Quantum Cloud Services (QCS) platform, the Company's machines can be integrated into any public, private or hybrid cloud. The Company also operates in Fremont, California; London, United Kingdom; Adelaide, Australia; British Columbia, Canada and Mumbai, India. The Company's revenue is derived from operations in the United States and the United Kingdom.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.